Status
Conditions
Treatments
About
Subjects will include patients diagnosed with breast cancer or hematological cancer who are planned for chemotherapy treatment with anthracycline or trastuzumab; and who have one or more risk factors for cardiovascular disease. Subjects will received an extra echocardiogram to determine if heart problems can be detected earlier.
Full description
Patients scheduled for potentially cardiotoxic chemotherapy would receive a baseline echocardiogram as per standard protocol which should be covered by the routine insurance Follow-up with an extra echocardiogram for research purposes would be performed after 2 cycles of that chemotherapy - supplied by the study Clinical assessment at 3 to 6 months including repeat echocardiography as per standard care with the research question as whether any differences in strain pattern between pre-chemo and post 2 cycles studies all identify patients who are more likely to have cardiac issues later. Patients will have standard of care visits at 3 month, 6 month and 12 month and will be evaluated for cardiac status and survival. Patient records will be reviewed at 5 years to check cardiac status and survival.
Sex
Ages
Volunteers
Inclusion criteria
Males and females 18 years and above
Willing and able to provide consent
Able to read
Patients diagnosed with breast cancer or hematological cancer who are planned for chemotherapy treatment with anthracycline or trastuzumab.
Patients at increased risk of cardiotoxicity with one or more risk factors for heart disease:
Exclusion criteria
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal